IRadimed Corp. (IRMD)

IRadimed Corp. stock has experienced significant positive movement, with the stock price increasing by approximately 72.01% to 77.84% over the last year. Key events impacting the stock include recognition as a top company by Forbes and TIME, strong financial performance with 17 consecutive quarters of record revenue, dividend payouts including a regular quarterly cash dividend of $0.17 per share for Q1 2025 and a special cash dividend of $0.50 per share, FDA clearance for the company's next-generation MRidium® 3870 IV Infusion Pump System, and a board transition with Anthony Vuoto retiring and Joe Kiani being appointed as a new director.

While some financial analysis platforms indicate that "IRMD Seasonality" is a factor that displays mean and median monthly returns to identify seasonal patterns, specific details regarding the nature of demand seasonality for IRadimed Corp.'s products and services are not explicitly provided in the available information.

IRadimed Corp. operates in the Health Care sector, specifically in the Medical/Dental Instruments or Health Care Equipment & Supplies industry, developing, manufacturing, marketing, and distributing MRI-compatible medical devices, accessories, disposables, and related services. Its major products include MRidium MRI Compatible IV Infusion Pump Systems, IRadimed 3880 MRI Compatible Patient Vital Signs Monitoring System, and the 3600 FMD1 Ferromagnetic Detection Device. Other offerings include non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. IRadimed Corp. sells its products primarily to hospitals and acute care facilities.

IRadimed Corp. distributes its MRI-compatible medical devices and services in the United States and internationally, with the majority of the company's revenue generated from the United States.

IRadimed Corp. has maintained a positive brand reputation over the past year, bolstered by its innovative MRI-compatible medical devices and consistent financial performance. The company's reputation has been positively impacted by industry recognition from Forbes and TIME, operational excellence with 17 consecutive quarters of record revenue, and unique product offerings as the only known provider of a non-magnetic IV infusion pump system specifically designed for safe use during MRI procedures. No significant negative events affecting IRadimed Corp.'s brand reputation in the past year were found in the provided information.

IRadimed Corp. has a diverse ownership structure, with institutional investors holding between 54.43% and 92.34% of the shares, while insiders own approximately 36.80% to 36.95%. Major institutional owners include BlackRock, Inc., Nine Ten Capital Management LLC, and Vanguard Group Inc, among others. Roger Susi, the CEO, is a significant individual shareholder.